Viking Therapeutics will launch a longship into phase 3 for the obesity drug VK2735 sooner than expected, with a clinical program expected to top $300 million. The biotech—which was launched into the ...
An upcoming trial result could change how investors think about the weight-loss drug market.
Pills that work similarly to currently available injectable medications represent the next wave of metabolic disorder drugs, and Viking Therapeutics is pushing its drug candidate to the forefront with ...
Hosted on MSN
Viking Therapeutics outlines dual Phase III obesity programs while advancing oral VK2735 and maintenance regimens
Brian Lian, President and CEO, highlighted several milestones in 2025, focusing on the obesity pipeline: "With the subcutaneous formulation of our lead molecule, VK2735, following the positive ...
I last updated on Viking Therapeutics, Inc. (VKTX) in October last year, covering the company's Q3 earnings and business updates, and issued stock with a Buy rating - my sixth straight Buy call, in ...
Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the 11 Best Short Squeeze Stocks to Buy Now. The company plans to accelerate the oral formulation of VK2735 following Phase 2 results and has also ...
The MarketWatch News Department was not involved in the creation of this content. 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes SAN DIEGO, March 26, 2026 ...
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results